Antibody DD-3B6/22 (Rylatt et al. and Whitaker et al., supra) that is directed toward an epitope near the ?? crosslink site present in crosslinked fibrin degradation products such as fragment DD is preferably used in the present process, but other antibodies reactive preferentially with D-dimer or other degradation products rather than with fibrin could also be used.